secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immuneering Corp (IMRX)
CIK:        0001790340
Form:       8-K
Filed at:   2023-04-19T23:59:59+00:00
Accession:  0001104659-23-047191
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immuneering announces $27.8M public offering of 2.73M shares at $11.00/share
----------------------------------------------------------------------------

- Entered underwriting agreement with Jefferies, Cowen and Guggenheim for 2,727,273 shares at $11.00/share.
- Expected net proceeds of approximately $27.8M after underwriting discounts and offering expenses.
- Proceeds to fund preclinical and clinical development of product candidates and for working capital.
- Closing expected on or about April 20, 2023, subject to customary closing conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1790340/000110465923047191/0001104659-23-047191-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1790340/000110465923047191/tm2313152d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-047191

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer